Skip to content

A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride

A Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04123665
Enrollment
98
Registered
2019-10-11
Start date
2013-05-28
Completion date
2013-12-11
Last updated
2020-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Keywords

Oral Health, Antiplaque, Gingivitis

Brief summary

The purpose of this study is to evaluate and compare the gingival health of a test dentifrice (0.454% weight by weight \[w/w\] stannous fluoride) to a negative control dentifrice by comparing modified gingival index, bleeding index and plaque index scores.

Detailed description

This will be a single-center, examiner-blinded, randomized, stratified, two-treatment parallel group, 24-week clinical study in healthy adult volunteers with moderate gingivitis. Eligible participants will be stratified based on gender and baseline mean whole mouth modified gingival index (MGI) score (Low: less than or equal to \[\<=\] 2.00/High greater than \[\>\]2.00) to ensure a balance in gingivitis across both treatment groups, and then randomized into one of two treatment groups. Treatment effect will be evaluated by comparing MGI , bleeding index and plaque index scores after 12 and 24 weeks use of a dentifrice containing 0.454% w/w stannous fluoride to a negative control dentifrice. During the 24 week treatment period, participants will apply a full ribbon of dentifrice to the head of a study toothbrush and brush their teeth in their usual manner at home for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.

Interventions

DRUGStannous fluoride

In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.

In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Consent :Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. * Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions. * General Health: Good general and mental health with, in the opinion of the investigator, no clinically significant and relevant abnormalities of medical history or oral examination. * Dental Health: A minimum of 20 natural teeth and a minimum of 40 gradable surfaces for: a) MGI, BI and PI. A scorable surface is defined as a surface that has 50% of the surface gradable. Third molars, orthodontically banded/ bonded, fully crowned or extensively restored or grossly carious teeth are not included in the tooth count; b) Moderate gingivitis present at the screening visit in the opinion of the investigator; c) Mean whole mouth MGI between 1.75 and 2.30 and mean whole mouth supra-gingival PI score 1.5 at Baseline Visit.

Exclusion criteria

* Pregnancy and breast-feeding: Women who are known to be pregnant or who are intending to become pregnant or women who are breast-feeding over the duration of the study. * Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * Tobacco Use: Current smokers or smokers who have quit within the past six months, prior to screening, or participants currently using smokeless forms of tobacco - e.g. chewing tobacco. * Concomitant Medications - Treatments Screening (Visit 1) 1. Currently taking antibiotics or requiring antibiotic use prior to dental prophylaxis or other dental procedures. 2. Currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition. 3. Currently taking a systemic medication which, in the opinion of the Investigator, could affect gingival condition (e.g. calcium channel blockers, or aspirin therapy). 4. Current use of a chlorhexidine mouthwash. Baseline (Visit 2) 5. Currently taking antibiotics or taken antibiotics in the previous 14 days or requiring antibiotic use prior to dental prophylaxis or other dental procedures. 6. Has taken an anti-inflammatory medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days. 7. Has taken a systemic medication which, in the opinion of the investigator, could affect gingival condition in the previous 14 days (e.g. calcium channel blockers, or aspirin therapy). * General Dentition Exclusions 1. Current active caries or periodontitis that may, in the opinion of the investigator, compromise the study outcomes or oral health of the participants if they participate in the study. 2. Restorations in a poor state of repair. 3. Partial dentures or orthodontic appliances. 4. Teeth bleaching within 12 weeks of screening. * Clinical Study/Experimental Medication 1. Participation in another clinical study or receipt of an investigational drug or investigational oral care product within 30 days of the Baseline Visit. 2. Previous participation in this study. * Substance abuse: Recent history (within the last year) of alcohol or other substance abuse. * Personnel: 1. Employed by the sponsor or the study site or members of their immediate family. 2. Employed by any dentifrice manufacturer or their immediate family. * Other Conditions: Any condition that would impact on the safety of the participant or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 WeeksAt Week 24BI-to assess bleeding elicited on probing as a measure of gingival condition. Gingivae were air dried and examiner assessed bleeding using a probe which was gently inserted into gingival crevice to depth of approximately(app)1millimeter(mm)and run around tooth(angle of app60\[degrees(deg)\] to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI assessed on facial and lingual gingival surfaces of each scorable tooth(7in each arch). 3scores were recorded buccally/labially,3scores lingually/palatally. All scorable teeth in one quadrant were probed first(app30seconds\[sec\])before recording number of gingival units which bled. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values(i.e.,0-2).BI score:0=no bleeding after30sec,1=bleeding upon probing after30sec,2=immediate bleeding observed. Lower scores indicate better results.

Secondary

MeasureTime frameDescription
Evaluation and Comparison of Gingival Health Measured by BI at 12 WeeksAt Week 12BI-to assess bleeding elicited on probing as a measure of gingival condition. Gingivae were air dried and examiner assessed bleeding using a probe which was gently inserted into gingival crevice to depth of app 1 mm and run around tooth (angle of app 60 deg to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI assessed on facial and lingual gingival surfaces of each scorable tooth (7in each arch). 3 scores were recorded buccally/ labially, 3scores lingually/ palatally. All scorable teeth in one quadrant were probed first (app 30 sec) before recording number of gingival units which bled. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-2). BI score:0=no bleeding after 30 sec, 1=bleeding upon probing after 30 sec,2=immediate bleeding observed. Lower scores indicate better results.
Evaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 WeeksAt Week 12 and Week 24BI-to assess bleeding elicited on probing as measure of gingival condition.Gingivae were air dried,examiner assessed bleeding using probe gently inserted into gingival crevice to depth of app.1mm and run around tooth(at angle of app.60deg to long axis of tooth),gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium.BI assessed on facial,lingual gingival surfaces of each scorable tooth(7in each arch).3scores recorded buccally/labially and 3lingually/palatally. All scorable teeth in 1quadrant probed first(app.30sec)before recording number of gingival units which bled.Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High: \>2.00).Whole mouth mean of BI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.BI scoring:0=no bleeding after 30sec,1=bleeding upon probing after 30sec,2=immediate bleeding observed. Lower scores- better results.
Evaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt Week 12 and Week 24BI-to assess bleeding elicited on probing as measure of gingival condition.Gingivae were air dried,examiner assessed bleeding using probe gently inserted into gingival crevice to depth of app.1mm and run around tooth(at angle of app.60deg to long axis of tooth),gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium.BI assessed on facial,lingual gingival surfaces of each scorable tooth(7in each arch).3scores recorded buccally/labially and 3lingually/palatally. All scorable teeth in 1quadrant probed first(app.30sec)before recording number of gingival units which bled.Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High: \>2.00).Whole mouth mean of BI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.BI scoring:0=no bleeding after 30sec,1=bleeding upon probing after 30sec,2=immediate bleeding observed. Lower scores- better results.
Evaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 WeeksAt Week 12 and Week 24MGI-to assess gingivitis symptoms on facial, lingual surfaces of each scorable tooth(7in each arch).2 scores recorded buccally/labially(papilla,margin),2lingually/palatally(papilla,margin).Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High:\>2.00).Whole mouth mean of MGI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.MGI scoring:0=absence of inflammation, 1=mild inflammation;slight change in color,little change in color;little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation;criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing,redness,edema,and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation;marked redness,edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion or ulceration. Lower scores indicate better results.
Evaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt Week 12 and Week 24MGI-to assess gingivitis symptoms on facial, lingual surfaces of each scorable tooth(7in each arch).2 scores recorded buccally/labially(papilla,margin),2lingually/palatally(papilla,margin).Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High:\>2.00).Whole mouth mean of MGI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.MGI scoring:0=absence of inflammation, 1=mild inflammation;slight change in color,little change in color;little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation;criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing,redness,edema,and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation;marked redness,edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion or ulceration. Lower scores indicate better results.
Evaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksAt Week 12 and Week 24Turesky Modification of Quigley Hein Plaque Index-to assess plaque on all gradable teeth. Participants rinsed the plaque in dye solution of 5milliliters(mL)of solution for 10 sec, then expectorated and rinsed with 10 mL of water for 10 sec and then expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-5). Disclosed plaque scored as:0=no plaque, 1=slight flecks of plaque at the cervical margin of the tooth,2=a thin continuous band of plaque (1mm or smaller) at the cervical margin of the tooth, 3=a band of plaque wider than 1mm but covering less than 1/3 of the area, 4=plaque covering at least 1/3 but less than 2/3 of the area,5=plaque covering 2/3 or more of the crown of the tooth. Lower scores indicate better results.
Evaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 WeeksAt Week 12 and Week 24MGI- to assess visual symptoms of gingivitis on facial and lingual surfaces of each scorable tooth (7 in each arch). 2scores recorded buccally/labially, 2scores lingually/palatally. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-4). Scoring was performed using standard dental light:0=absence of inflammation,1=mild inflammation;slight change in color,little change in color; little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation; criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion,or ulceration. Lower scores indicate better results.

Other

MeasureTime frameDescription
Number of Bleeding Sites After 12 and 24 WeeksAt Week 12 and Week 24Number of gingival bleeding sites were measured as part of bleeding index via a single examiner using a color-coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. For each participant, the scoring system used to measure bleeding sites is as follows: 0= no bleeding after 30 sec, 1= bleeding upon probing after 30 sec, 2= immediate bleeding observed. Lower bleeding sites indicate better results.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from one center in United States.

Pre-assignment details

A total of 125 participants were screened for the study. Of these, 98 participants were enrolled and allocated to a randomized treatment. 27 participants were not enrolled, of which, 19 did not meet study criteria, 3 lost to follow-up and 5 withdrew their consent.

Participants by arm

ArmCount
Experimental Test Stannous Fluoride Dentifrice
In this arm, participants applied a full ribbon of dentifrice (0.454% weight by weight \[w/w\] stannous fluoride) to the bristles of a study toothbrush and brushed their teeth in their usual manner for one timed minute twice daily (morning and evening) and recorded on their study diary completed brushings for 24 weeks.
50
Control Sodium Monofluorophosphate Dentifrice
In this arm, participants applied a full ribbon of negative control dentifrice (1000 parts per million \[ppm\] fluoride as sodium monofluorophosphate \[SMFP\] to the bristles of a study toothbrush and brushed their teeth in their usual manner for one timed minute twice daily (morning and evening) and recorded on their study diary completed brushings for 24 weeks.
48
Total98

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up10
Overall StudyWithdrawal by Subject70

Baseline characteristics

CharacteristicControl Sodium Monofluorophosphate DentifriceExperimental Test Stannous Fluoride DentifriceTotal
Age, Continuous38.8 Years
STANDARD_DEVIATION 12.44
39.5 Years
STANDARD_DEVIATION 14.55
39.2 Years
STANDARD_DEVIATION 13.49
Baseline Modified Gingival Index (MGI) strata
Female
MGI less than or equal to [<=] 2.00
16 Participants18 Participants34 Participants
Baseline Modified Gingival Index (MGI) strata
Female
MGI more than [>] 2.00
15 Participants16 Participants31 Participants
Baseline Modified Gingival Index (MGI) strata
Male
MGI less than or equal to [<=] 2.00
5 Participants5 Participants10 Participants
Baseline Modified Gingival Index (MGI) strata
Male
MGI more than [>] 2.00
12 Participants11 Participants23 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
8 Participants4 Participants12 Participants
Race (NIH/OMB)
More than one race
0 Participants2 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
39 Participants43 Participants82 Participants
Sex: Female, Male
Female
31 Participants34 Participants65 Participants
Sex: Female, Male
Male
17 Participants16 Participants33 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 500 / 48
other
Total, other adverse events
0 / 501 / 48
serious
Total, serious adverse events
0 / 500 / 48

Outcome results

Primary

Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks

BI-to assess bleeding elicited on probing as a measure of gingival condition. Gingivae were air dried and examiner assessed bleeding using a probe which was gently inserted into gingival crevice to depth of approximately(app)1millimeter(mm)and run around tooth(angle of app60\[degrees(deg)\] to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI assessed on facial and lingual gingival surfaces of each scorable tooth(7in each arch). 3scores were recorded buccally/labially,3scores lingually/palatally. All scorable teeth in one quadrant were probed first(app30seconds\[sec\])before recording number of gingival units which bled. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values(i.e.,0-2).BI score:0=no bleeding after30sec,1=bleeding upon probing after30sec,2=immediate bleeding observed. Lower scores indicate better results.

Time frame: At Week 24

Population: Intent-to-treat (ITT) population \[N=91\] included all participants who received study treatment and had at least one post-baseline efficacy measurement. Number analyzed in this outcome measure signifies those who were evaluated.

ArmMeasureValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks0.11 Score on scaleStandard Deviation 0.094
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks0.19 Score on scaleStandard Deviation 0.105
p-value: <0.000195% CI: [-0.11, -0.04]ANCOVA
Secondary

Evaluation and Comparison of Gingival Health Measured by BI at 12 Weeks

BI-to assess bleeding elicited on probing as a measure of gingival condition. Gingivae were air dried and examiner assessed bleeding using a probe which was gently inserted into gingival crevice to depth of app 1 mm and run around tooth (angle of app 60 deg to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI assessed on facial and lingual gingival surfaces of each scorable tooth (7in each arch). 3 scores were recorded buccally/ labially, 3scores lingually/ palatally. All scorable teeth in one quadrant were probed first (app 30 sec) before recording number of gingival units which bled. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-2). BI score:0=no bleeding after 30 sec, 1=bleeding upon probing after 30 sec,2=immediate bleeding observed. Lower scores indicate better results.

Time frame: At Week 12

Population: ITT population \[N=91\] included all participants who were enrolled and randomly allocated to treatment and are analyzed in the groups to which they were randomized.

ArmMeasureValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by BI at 12 Weeks0.11 Score on scaleStandard Deviation 0.104
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by BI at 12 Weeks0.23 Score on scaleStandard Deviation 0.124
Secondary

Evaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 Weeks

BI-to assess bleeding elicited on probing as measure of gingival condition.Gingivae were air dried,examiner assessed bleeding using probe gently inserted into gingival crevice to depth of app.1mm and run around tooth(at angle of app.60deg to long axis of tooth),gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium.BI assessed on facial,lingual gingival surfaces of each scorable tooth(7in each arch).3scores recorded buccally/labially and 3lingually/palatally. All scorable teeth in 1quadrant probed first(app.30sec)before recording number of gingival units which bled.Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High: \>2.00).Whole mouth mean of BI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.BI scoring:0=no bleeding after 30sec,1=bleeding upon probing after 30sec,2=immediate bleeding observed. Lower scores- better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on a subgroup of ITT population (included all participants who received study treatment and had at least one post-baseline efficacy measurement) that included participants with MGI \>2.00 \[N=52\] . Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 12 with baseline MGI >2.000.11 Score on scaleStandard Deviation 0.094
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 24 with baseline MGI >2.000.12 Score on scaleStandard Deviation 0.092
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 12 with baseline MGI >2.000.25 Score on scaleStandard Deviation 0.144
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 24 with baseline MGI >2.000.21 Score on scaleStandard Deviation 0.117
Secondary

Evaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 Weeks

BI-to assess bleeding elicited on probing as measure of gingival condition.Gingivae were air dried,examiner assessed bleeding using probe gently inserted into gingival crevice to depth of app.1mm and run around tooth(at angle of app.60deg to long axis of tooth),gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium.BI assessed on facial,lingual gingival surfaces of each scorable tooth(7in each arch).3scores recorded buccally/labially and 3lingually/palatally. All scorable teeth in 1quadrant probed first(app.30sec)before recording number of gingival units which bled.Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High: \>2.00).Whole mouth mean of BI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.BI scoring:0=no bleeding after 30sec,1=bleeding upon probing after 30sec,2=immediate bleeding observed. Lower scores- better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on a subgroup of ITT population (included all participants who received study treatment and had at least one post-baseline efficacy measurement) that included participants with MGI \<=2.00 \[N=39\] . Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 WeeksAt week 12 with baseline MGI <=2.000.11 Score on scaleStandard Deviation 0.119
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 WeeksAt week 24 with baseline MGI <=2.000.10 Score on scaleStandard Deviation 0.097
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 WeeksAt week 12 with baseline MGI <=2.000.21 Score on scaleStandard Deviation 0.093
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by BI Indices in Low MGI Subgroups (<=2.00) After 12 and 24 WeeksAt week 24 with baseline MGI <=2.000.16 Score on scaleStandard Deviation 0.082
Secondary

Evaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 Weeks

MGI-to assess gingivitis symptoms on facial, lingual surfaces of each scorable tooth(7in each arch).2 scores recorded buccally/labially(papilla,margin),2lingually/palatally(papilla,margin).Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High:\>2.00).Whole mouth mean of MGI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.MGI scoring:0=absence of inflammation, 1=mild inflammation;slight change in color,little change in color;little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation;criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing,redness,edema,and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation;marked redness,edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion or ulceration. Lower scores indicate better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on a subgroup of ITT population (included all participants who received study treatment and had at least one post-baseline efficacy measurement) that included participants with MGI \>2.00 \[N=52\] . Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 12 with baseline MGI >2.001.54 Score on scaleStandard Deviation 0.364
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 24 with baseline MGI >2.001.57 Score on scaleStandard Deviation 0.324
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 12 with baseline MGI >2.001.96 Score on scaleStandard Deviation 0.22
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in High MGI Subgroup (>2.00) at 12 and 24 WeeksAt week 24 with baseline MGI >2.001.93 Score on scaleStandard Deviation 0.231
Secondary

Evaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 Weeks

MGI-to assess gingivitis symptoms on facial, lingual surfaces of each scorable tooth(7in each arch).2 scores recorded buccally/labially(papilla,margin),2lingually/palatally(papilla,margin).Participants stratified based upon gender and baseline MGI score(Low:\<=2.00,High:\>2.00).Whole mouth mean of MGI calculated by-taking average overall tooth sites assessed;to compare magnitude of differences in two strata.MGI scoring:0=absence of inflammation, 1=mild inflammation;slight change in color,little change in color;little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation;criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing,redness,edema,and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation;marked redness,edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion or ulceration. Lower scores indicate better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on a subgroup of ITT population (included all participants who received study treatment and had at least one post-baseline efficacy measurement) that included participants with MGI \<=2.00 \[N=39\] . Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 WeeksAt week 12 with baseline MGI <=2.001.26 Score on scaleStandard Deviation 0.409
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 WeeksAt week 24 with baseline MGI <=2.001.29 Score on scaleStandard Deviation 0.383
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 WeeksAt week 12 with baseline MGI <=2.001.74 Score on scaleStandard Deviation 0.199
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by MGI Indices in Low MGI Subgroup (<=2.00) at 12 and 24 WeeksAt week 24 with baseline MGI <=2.001.60 Score on scaleStandard Deviation 0.319
Secondary

Evaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 Weeks

MGI- to assess visual symptoms of gingivitis on facial and lingual surfaces of each scorable tooth (7 in each arch). 2scores recorded buccally/labially, 2scores lingually/palatally. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-4). Scoring was performed using standard dental light:0=absence of inflammation,1=mild inflammation;slight change in color,little change in color; little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation; criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion,or ulceration. Lower scores indicate better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on ITT population \[N=91\] which included all participants who received study treatment and had at least one post-baseline efficacy measurement. Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 WeeksAt week 121.43 Score on scaleStandard Deviation 0.403
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 WeeksAt week 241.46 Score on scaleStandard Deviation 0.373
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 WeeksAt week 121.87 Score on scaleStandard Deviation 0.237
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Gingival Health Measured by Modified Gingival Index (MGI) at 12 and 24 WeeksAt week 241.78 Score on scaleStandard Deviation 0.316
Secondary

Evaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 Weeks

Turesky Modification of Quigley Hein Plaque Index-to assess plaque on all gradable teeth. Participants rinsed the plaque in dye solution of 5milliliters(mL)of solution for 10 sec, then expectorated and rinsed with 10 mL of water for 10 sec and then expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e.,0-5). Disclosed plaque scored as:0=no plaque, 1=slight flecks of plaque at the cervical margin of the tooth,2=a thin continuous band of plaque (1mm or smaller) at the cervical margin of the tooth, 3=a band of plaque wider than 1mm but covering less than 1/3 of the area, 4=plaque covering at least 1/3 but less than 2/3 of the area,5=plaque covering 2/3 or more of the crown of the tooth. Lower scores indicate better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on ITT population \[N=91\] which included all participants who received study treatment and had at least one post-baseline efficacy measurement. Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksOverall analysis at week 122.60 Score on scaleStandard Deviation 0.454
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksOverall analysis at week 242.56 Score on scaleStandard Deviation 0.527
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksInterproximal analysis at week 122.82 Score on scaleStandard Deviation 0.399
Experimental Test Stannous Fluoride DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksInterproximal analysis at week 242.78 Score on scaleStandard Deviation 0.469
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksInterproximal analysis at week 243.00 Score on scaleStandard Deviation 0.317
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksOverall analysis at week 122.90 Score on scaleStandard Deviation 0.407
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksInterproximal analysis at week 123.05 Score on scaleStandard Deviation 0.354
Control Sodium Monofluorophosphate DentifriceEvaluation and Comparison of Supra-gingival Plaque Levels Measured by Overall and Inter-proximal Plaque Index (PI) at 12 and 24 WeeksOverall analysis at week 242.83 Score on scaleStandard Deviation 0.355
Other Pre-specified

Number of Bleeding Sites After 12 and 24 Weeks

Number of gingival bleeding sites were measured as part of bleeding index via a single examiner using a color-coded periodontal probe. The probe was engaged approximately 1 mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. For each participant, the scoring system used to measure bleeding sites is as follows: 0= no bleeding after 30 sec, 1= bleeding upon probing after 30 sec, 2= immediate bleeding observed. Lower bleeding sites indicate better results.

Time frame: At Week 12 and Week 24

Population: Analysis was performed on ITT population \[N=91\] which included all participants who received study treatment and had at least one post-baseline efficacy measurement. Number analyzed included participants with available data for each specified category.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Test Stannous Fluoride DentifriceNumber of Bleeding Sites After 12 and 24 WeeksAt week 1212.26 Number of bleeding sitesStandard Deviation 10.468
Experimental Test Stannous Fluoride DentifriceNumber of Bleeding Sites After 12 and 24 WeeksAt week 2412.69 Number of bleeding sitesStandard Deviation 10.12
Control Sodium Monofluorophosphate DentifriceNumber of Bleeding Sites After 12 and 24 WeeksAt week 1223.92 Number of bleeding sitesStandard Deviation 11.024
Control Sodium Monofluorophosphate DentifriceNumber of Bleeding Sites After 12 and 24 WeeksAt week 2420.19 Number of bleeding sitesStandard Deviation 9.225

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026